CG
LXRX icon

Clinton Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Clinton Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-31,283
Closed -$433K – 995
2016
Q4 		$433K Sell
31,283
-6,798
-18% -$109K 0.03% 607
2016
Q3 		$688K Buy
38,081
+17,661
+86% +$284K 0.03% 598
2016
Q2 		$293K Buy
20,420
+8,306
+69% +$113K 0.01% 752
2016
Q1 		$145K Buy
+12,114
New +$127K 0.01% 831
2015
Q4 		– Sell
-29,458
Closed -$316K – 811
2015
Q3 		$316K Buy
+29,458
New +$322K 0.03% 541

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Clinton Group's LXRX Position: Q1 2017 in Review

Clinton Group sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 31,283 shares — an estimated $433K sold.

Clinton Group first reported a position in LXRX in Q3 2015 and held it in 5 quarters. The position peaked at $688K in Q3 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

  • Clinton Group reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Clinton Group sold 31,283 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $433K.
  • Clinton Group first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • Clinton Group's Lexicon Pharmaceuticals position peaked at $688K in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on Clinton Group's 13F filing for Q1 2017, filed 10 May 2017.